Literature DB >> 21097656

A decade of mycophenolate mofetil for lupus nephritis: is the glass half-empty or half-full?

Dimitrios T Boumpas, George K Bertsias, James E Balow.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21097656      PMCID： PMC3535222          DOI： 10.1136/ard.2010.139683

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  20 in total

1.  Sequential therapies for proliferative lupus nephritis.

Authors:  Gabriel Contreras; Victoriano Pardo; Baudouin Leclercq; Oliver Lenz; Elaine Tozman; Patricia O'Nan; David Roth
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245

2.  Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.

Authors:  Ellen M Ginzler; Mary Anne Dooley; Cynthia Aranow; Mimi Y Kim; Jill Buyon; Joan T Merrill; Michelle Petri; Gary S Gilkeson; Daniel J Wallace; Michael H Weisman; Gerald B Appel
Journal:  N Engl J Med       Date:  2005-11-24       Impact factor: 91.245

3.  Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.

Authors:  Tak-Mao Chan; Kai-Chung Tse; Colin Siu-On Tang; Mo-Yin Mok; Fu-Keung Li
Journal:  J Am Soc Nephrol       Date:  2005-02-23       Impact factor: 10.121

4.  Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial.

Authors:  C Grootscholten; G Ligtenberg; E C Hagen; A W L van den Wall Bake; J W de Glas-Vos; M Bijl; K J Assmann; J A Bruijn; J J Weening; H C van Houwelingen; R H W M Derksen; J H M Berden
Journal:  Kidney Int       Date:  2006-07-05       Impact factor: 10.612

5.  Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis.

Authors:  Loke Meng Ong; Lai Seong Hooi; Teck Onn Lim; Bak Leong Goh; Ghazali Ahmad; Rozina Ghazalli; Sue Mei Teo; Hin Seng Wong; Si Yen Tan; Wan Shaariah; Chwee Choon Tan; Zaki Morad
Journal:  Nephrology (Carlton)       Date:  2005-10       Impact factor: 2.506

6.  Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group.

Authors:  T M Chan; F K Li; C S Tang; R W Wong; G X Fang; Y L Ji; C S Lau; A K Wong; M K Tong; K W Chan; K N Lai
Journal:  N Engl J Med       Date:  2000-10-19       Impact factor: 91.245

7.  Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.

Authors:  Frédéric A Houssiau; Carlos Vasconcelos; David D'Cruz; Gian Domenico Sebastiani; Enrique de Ramon Garrido Ed; Maria Giovanna Danieli; Daniel Abramovicz; Daniel Blockmans; Alessandro Mathieu; Haner Direskeneli; Mauro Galeazzi; Ahmet Gül; Yair Levy; Peter Petera; Rajko Popovic; Radmila Petrovic; Renato Alberto Sinico; Roberto Cattaneo; Josep Font; Geneviève Depresseux; Jean-Pierre Cosyns; Ricard Cervera
Journal:  Arthritis Rheum       Date:  2002-08

8.  Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis.

Authors:  D T Boumpas; H A Austin; E M Vaughn; J H Klippel; A D Steinberg; C H Yarboro; J E Balow
Journal:  Lancet       Date:  1992-09-26       Impact factor: 79.321

9.  Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy.

Authors:  D T Boumpas; H A Austin; E M Vaughan; C H Yarboro; J H Klippel; J E Balow
Journal:  Ann Intern Med       Date:  1993-09-01       Impact factor: 25.391

10.  Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs.

Authors:  H A Austin; J H Klippel; J E Balow; N G le Riche; A D Steinberg; P H Plotz; J L Decker
Journal:  N Engl J Med       Date:  1986-03-06       Impact factor: 91.245
View more
  1 in total

1.  Connective tissue diseases: Lupus nephritis-winning a few battles but not the war.

Authors:  George K Bertsias; Dimitrios T Boumpas
Journal:  Nat Rev Rheumatol       Date:  2011-06-21       Impact factor: 20.543
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.